Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.

Literature DB >> 20705771

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.

Aya Kuwabara, Anna Babb, Amr Ibrahim, Dragana Milojkovic, Jane Apperley, Marco Bua, Alistair Reid, Letizia Foroni, Katayoun Rezvani, John Goldman, David Marin.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2010 PMID： 20705771 PMCID： PMC2924222 DOI： 10.1182/blood-2010-04-280206

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

5 in total

1. Pregnancy among patients with chronic myeloid leukemia treated with imatinib.

Authors: Patricia Ault; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Miloslav Beran; Mary Beth Rios; Charles Koller; Francis Giles; Michael Keating; Moshe Talpaz; Jorge Cortes
Journal: J Clin Oncol Date: 2006-01-30 Impact factor: 44.544

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors: Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal: N Engl J Med Date: 2006-12-07 Impact factor: 91.245

3. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

Authors: Hyun-Gyung Goh; Yoo-Jin Kim; Dong-Wook Kim; Hyeoung-Joon Kim; Soo-Hyun Kim; Se-Eun Jang; Jeong Lee; Dongho Kim; Wan-Seok Kim; Sa-Hee Park; Il-Young Kweon
Journal: Leuk Lymphoma Date: 2009-06

4. The effects of imatinib on pregnancy outcome.

Authors: Seonaid M Pye; Jorge Cortes; Patricia Ault; Alan Hatfield; Hagop Kantarjian; Richard Pilot; Gianantonio Rosti; Jane F Apperley
Journal: Blood Date: 2008-03-05 Impact factor: 22.113

Review 5. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors: Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544

5 in total

6 in total

Review 1. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

Authors: A John Barrett; Sawa Ito
Journal: Blood Date: 2015-04-07 Impact factor: 22.113

Review 2. Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.

Authors: Christopher A Eide; Thomas O'Hare
Journal: Curr Hematol Malig Rep Date: 2015-06 Impact factor: 3.952

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.

1. Pregnancy among patients with chronic myeloid leukemia treated with imatinib.

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

3. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

4. The effects of imatinib on pregnancy outcome.

Review 5. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Review 1. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

Review 2. Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.

3. Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy.

4. Recent advances in the path toward the cure for chronic myeloid leukemia.

Review 5. Deep molecular responses for treatment-free remission in chronic myeloid leukemia.

6. [The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)].